{
    "organizations": [],
    "uuid": "987cb5085c875a19c0a2309cb18d84648f025995",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eiger-biopharmaceuticals-announces/brief-eiger-biopharmaceuticals-announces-proposed-public-offering-of-common-stock-idUSASC0A3GC",
    "ord_in_thread": 0,
    "title": "BRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Eiger BioPharmaceuticals Inc:\n* EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK\n* EIGER BIOPHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK\n* EIGER BIOPHARMACEUTICALS - PLANS TO USE NET PROCEEDS TO FUND PLANNED PHASE 3 CLINICAL TRIAL OF LONAFARNIB IN HEPATITIS DELTA VIRUS INFECTION, OTHERS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-24T04:22:00.000+03:00",
    "crawled": "2018-05-24T20:25:28.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "eiger",
        "biopharmaceuticals",
        "announces",
        "proposed",
        "public",
        "offering",
        "common",
        "stock",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "commenced",
        "underwritten",
        "public",
        "offering",
        "common",
        "stock",
        "eiger",
        "biopharmaceuticals",
        "plan",
        "use",
        "net",
        "proceeds",
        "fund",
        "planned",
        "phase",
        "clinical",
        "trial",
        "lonafarnib",
        "hepatitis",
        "delta",
        "virus",
        "infection",
        "others",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}